ERBB2 OVEREXPRESSION Detail (hg19) (ERBB2)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr17:37,844,167-37,884,915 |
| hg38 | chr17:39,687,914-39,728,662 View the variant detail on this assembly version. |
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Links
| Type | Database | ID | Link |
|---|---|---|---|
| Gene | MIM | ||
| HGNC | |||
| Ensembl | |||
| NCBI | |||
| Gene Cards | |||
| OncoKB |
| Type | Database | ID | Link |
|---|---|---|---|
| Variant | TogoVar | ||
| COSMIC | |||
| MONDO |
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
| Disease | Drug | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| head and neck squamous cell carcinoma | Lapatinib | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 28061634 | Detail |
| Her2-receptor positive breast cancer | Trastuzumab Emtansine | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 28526536 | Detail |
| pancreatic cancer | Capecitabine,Trastuzumab | B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 4 | 22374460 | Detail |
| pancreatic cancer | Trastuzumab,Gemcitabine | B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 4 | 15581051 | Detail |
| salivary gland cancer | Paclitaxel,Trastuzumab | C |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
2 | 23826550 | Detail |
| salivary gland cancer | Trastuzumab,Zoledronic Acid,Capecitabine | C |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 20504363 | Detail |
DisGeNET
[No Data.]
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| Case report of a 60-year old patient with p16 positive tumor of the tonsil with lung metastases afte... | CIViC Evidence | Detail |
| Trastuzumab emtansine has its indication for patients with HER2-positive metastatic breast cancer af... | CIViC Evidence | Detail |
| This is Phase II trial of Trastuzumab and capecitabine as first line treatment in patients with IHC ... | CIViC Evidence | Detail |
| Patients with metastatic pancreatic cancer with IHC 2+/3+ HER2 received gemcitabine and Trastuzumab ... | CIViC Evidence | Detail |
| Case report of a 61-year-old caucasian male with a renal mass and subsequent liver metastases. Histo... | CIViC Evidence | Detail |
| Case report of a a 58 year old man with multiple bone metastases after local therapy of a carcinoma ... | CIViC Evidence | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- -
- Genome
- hg19
- Position
- chr17:37,844,167-37,884,915
- Variant Type
- cnv
- Variant (CIViC) (CIViC Variant)
- OVEREXPRESSION
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/875
Genome browser